Literature DB >> 6631010

Murine hybridomas secreting natural monoclonal antibodies reacting with self antigens.

G Dighiero, P Lymberi, J C Mazié, S Rouyre, G S Butler-Browne, R G Whalen, S Avrameas.   

Abstract

Spleen cells from nonimmunized BALB/c mice were fused with two nonsecreting myeloma lines. The hybrids were selected in HAT medium and screened for Ig production and for antibody activity against actin, tubulin, myosin, thyroglobulin, myoglobin, spectrin, dsDNA, fetuin, and transferrin. Among 161 hybrids secreting Ig, three were found to react with DNA, one with thyroglobulin, and one mainly with myosin. Two of these hybrids could be propagated and further characterized. On the basis of inhibition experiments, one was found to be directed against dsDNA; the other was directed mainly against myosin but at the same time reacted significantly with actin, tubulin, spectrin, and dsDNA. Reactivity with myosin seemed to be concentrated in the light meromyosin subfragment, known to be rich in alpha-helical structure. These results indicate: 1) There are reactive B cell clones directed against self antigens. 2) The antibody specificities found for these antibodies are very similar to those found for natural antibodies in normal human serum and for human monoclonal Ig. 3) The widespread reactivity found for the clone mainly reacting with myosin raises the possibility that the determinant recognized by this antibody is a conformational structure that possibly is associated with alpha-helical structures.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6631010

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  72 in total

1.  Polyreactive antigen-binding B (PAB-) cells are widely distributed and the PAB population consists of both B-1+ and B-1- phenotypes.

Authors:  Z-H Zhou; A L Notkins
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

2.  Sequence-specific binding of normal serum immunoglobulin M to exposed protein C-termini.

Authors:  Alex V Sokoloff; Marissa Puckett; James J Ludtke; Bryan Fetterly
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

Review 3.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

Review 4.  Immunotoxicology: suppressive and stimulatory effects of drugs and environmental chemicals on the immune system. A discussion.

Authors:  E Gleichmann; I Kimber; I F Purchase
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

5.  Polyspecific human and murine antibodies to diphtheria and tetanus toxoids and phospholipids.

Authors:  M Sutjita; A Hohmann; R Comacchio; J Bradley
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

6.  Hybrids from normal, germ free, nude and neonatal mice produce monoclonal autoantibodies to eight different intracellular structures.

Authors:  J R Underwood; J S Pedersen; P J Chalmers; B H Toh
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

7.  Human multiple organ-reactive monoclonal autoantibody recognizes growth hormone and a 35,000-molecular weight protein.

Authors:  J Satoh; K Essani; P R McClintock; A L Notkins
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

Review 8.  Regulation of the antibody repertoire through control of HCDR3 diversity.

Authors:  H W Schroeder; G C Ippolito; S Shiokawa
Journal:  Vaccine       Date:  1998 Aug-Sep       Impact factor: 3.641

9.  Both VH and VL chains of polyreactive IgM antibody are required for polyreactivity: expression of Fab in Escherichia coli.

Authors:  S C Cheung; S Takeda; A L Notkins
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

10.  Multiple autoantigen binding capabilities of mouse monoclonal antibodies selected for rheumatoid factor activity.

Authors:  R L Rubin; R S Balderas; E M Tan; F J Dixon; A N Theofilopoulos
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.